Health Affairs September 29, 2023
Suhasini Ravi, Zachary Baron, Andrew Twinamatsiko

The legal fight over the Medicare drug price negotiation program enacted under the Inflation Reduction Act (IRA) has entered a new phase. As we covered in previous articles here, the U.S. Department of Health and Human Services’ (HHS) authority to directly negotiate the price Medicare pays for a few single-sourced, high-cost drugs faces a slew of constitutional and statutory challenges. Merck is one of multiple pharmaceutical companies and trade associations to file lawsuits across the country, several of which involve similar claims over the constitutionality of the IRA drug negotiation program.

These lawsuits are still in the early stages of litigation, with months to go before any resolution. The Chamber of Commerce filed a motion for a preliminary injunction against...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech
MedPAC mulls over physician compensation through Medicare
Voters reject repealing the Affordable Care Act but are wary of Medicare for All: poll
The decline of anesthesia reimbursements: 5 key considerations
Coding changes to Medicare telehealth services for CY 2024
Insurance companies manipulating generic prescription drug prices in Medicare: Study

Share This Article